Drug intelligence / Profile preview

AKA-2

Development stage: Preclinical
Lead developer: Acıbadem Labcell
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Injection

Overview

AKA-2 (Acıbadem Kanser Asısı-2) is an autologous dendritic cell (DC) vaccine developed by Acıbadem Labcell for the treatment of hematological malignancies. The therapy involves the isolation of a patient's own dendritic cells, which are then pulsed ex vivo with tumor-specific synthetic antigens. These engineered cells are subsequently re-administered to the patient to function as potent antigen-presenting cells. The primary goal of AKA-2 is to stimulate and expand a robust, antigen-specific T-cell response capable of identifying and eliminating tumor cells. It is currently in development for various indications within hemato-oncology.

Other names: Acıbadem Kanser Asısı-2Synthetic antigen-pulsed DC vaccine

Beyond the preview

Go deeper on AKA-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKA-2.

Explore the full profile